Solu-Medrol Indications/Uses

Glucocorticoids should only be considered as a purely symptomatic treatment, unless in case of some endocrine disorders, where they are used as substitution treatment.
ANTI-INFLAMMATORY TREATMENT: Rheumatic Disorders (as adjunctive therapy for short-term administration in the management of an acute episode or exacerbation): post-traumatic osteoarthritis; synovitis or osteoarthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); acute and subacute bursitis; epicondylitis; acute non-specific tenosynovitis; acute gouty arthritis; psoriatic arthritis; ankylosing spondylitis.
Collagen Diseases (during an exacerbation or as maintenance therapy in selected cases): systemic lupus erythematosus; acute rheumatic carditis; systemic dermatomyositis (polymyositis); polyarteritis nodosa; Good pasture's syndrome.
Dermatologic Diseases: pemphigus; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; bullous dermatitis herpetiformis; severe seborrheic dermatitis; severe psoriasis; mycosis fungoides; urticaria.
Allergic States (to control severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment): bronchial asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions; urticarial transfusion reactions; acute non-infectious laryngeal edema (epinephrine is the drug of first choice).
Ophthalmic Diseases (severe acute and chronic allergic and inflammatory processes involving the eye): herpes zoster ophthalmicus; iritis, iridocyclitis; chorioretinitis; diffuse posterior uveitis and choroiditis; optic neuritis; sympathetic ophthalmia.
Gastrointestinal Diseases (to manage critical periods of the disease): ulcerative colitis (systemic therapy); Crohn's disease (systemic therapy).
Respiratory Diseases: symptomatic pulmonary sarcoidosis berylliosis; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculous chemotherapy; Loeffler's syndrome not manageable by other means; aspiration pneumonitis.
Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia of the idiopathic type or that due to lupus erythematosus.
IMMUNOSUPPRESIVE TREATMENT: Organ Transplantation.
TREATMENT OF HEMATOLOGICAL AND ONCOLOGICAL DISORDERS: Hematologic Disorders: acquired (autoimmune) hemolytic anemia; idiopathic thrombocytopenia purpura in adults (IV only; IM Administration is contraindicated); secondary thrombocytopenia in adults; erythroblastopenia (RBC anemia); congenital (erythroid) hypoplastic anemia.
Oncological Diseases: For palliative management of: leukemias and lymphomas in adults; acute leukemia of childhood.
TREATMENT OF SHOCK STATES: Shock secondary to adrenocortical insufficiency or shock unresponsive to conventional therapy when adrenal cortical insufficiency may be present. (Hydrocortisone is generally the drug of choice. When mineralocorticoid activity is undesirable, methylprednisolone may be preferred.)
Hemorrhagic, traumatic and surgical shock unresponsive to standard therapy.
Although there are no well controlled (double-blind placebo) clinical trials, data from experimental animal models indicate that SOLU-MEDROL may be useful in shock states in which standard therapy e.g., fluid replacement has not been effective.
OTHERS: Nervous system: cerebral edema from tumour - primary or metastatic and/or associated with surgical or radiation therapy or head trauma; acute exacerbations of multiple sclerosis; acute spinal cord injury. The treatment should begin within 8 hours of injury.
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapy.
Trichinosis with neurologic or myocardial involvement.
Prevention of nausea and vomiting associated with cancer chemotherapy.
ENDOCRINE DISORDERS: primary or secondary adrenocortical insufficiency; acute adrenocortical insufficiency; for these indications, the drugs of choice are hydrocortisone or cortisone. Synthetic analogues can be used in certain circumstances if they are combined with mineralocorticoids; preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful; congenital adrenal hyperplasia; non-suppurative thyroiditis; hypercalcemia associated with cancer.